Pharmacologic Treatment of Dyslipidemia in Diabetes: A Case for Therapies in Addition to Statins

Abeer Anabtawi, Patrick M. Moriarty, John M. Miles

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Purpose of Review: The purpose of the study is to review the use of statins and the role of both non-statin lipid-lowering agents and diabetes-specific medications in the treatment of diabetic dyslipidemia. Recent Findings: Statins have a primary role in the treatment of dyslipidemia in people with type 2 diabetes, defined as triglyceride levels >200 mg/dl and HDL cholesterol levels <40 mg/dL. A number of clinical trials suggest that treatment with a fibrate may reduce cardiovascular events. However, the results of these trials are inconsistent, probably because many of their participants did not have dyslipidemia. The choice of medications used to treat diabetes can have major implications regarding management of dyslipidemia; metformin, GLP-1 agonists, and pioglitazone all have favorable lipid effects. These agents, as well as the new SGLT2 inhibitors, may reduce cardiovascular events. Summary: Management of dyslipidemia in people with type 2 diabetes should start with statin therapy and optimal glycemic control with agents that have favorable lipid and cardiovascular effects. We believe that there is a role for adding fenofibrate to moderate-intensity statins in selected patients with true dyslipidemia. We propose an algorithm for selecting add-on medications for diabetes (after metformin) based on lipid status.

Original languageEnglish (US)
Article number62
JournalCurrent Cardiology Reports
Volume19
Issue number7
DOIs
StatePublished - Jul 1 2017
Externally publishedYes

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Dyslipidemias
Lipids
Metformin
pioglitazone
Type 2 Diabetes Mellitus
Therapeutics
Fenofibrate
Fibric Acids
Glucagon-Like Peptide 1
HDL Cholesterol
Triglycerides
Clinical Trials

Keywords

  • Cardiovascular disease
  • Fibrates
  • Type 2 diabetes

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Pharmacologic Treatment of Dyslipidemia in Diabetes : A Case for Therapies in Addition to Statins. / Anabtawi, Abeer; Moriarty, Patrick M.; Miles, John M.

In: Current Cardiology Reports, Vol. 19, No. 7, 62, 01.07.2017.

Research output: Contribution to journalReview article

Anabtawi, Abeer ; Moriarty, Patrick M. ; Miles, John M. / Pharmacologic Treatment of Dyslipidemia in Diabetes : A Case for Therapies in Addition to Statins. In: Current Cardiology Reports. 2017 ; Vol. 19, No. 7.
@article{9fc4214aac50458fb74573bf12f59931,
title = "Pharmacologic Treatment of Dyslipidemia in Diabetes: A Case for Therapies in Addition to Statins",
abstract = "Purpose of Review: The purpose of the study is to review the use of statins and the role of both non-statin lipid-lowering agents and diabetes-specific medications in the treatment of diabetic dyslipidemia. Recent Findings: Statins have a primary role in the treatment of dyslipidemia in people with type 2 diabetes, defined as triglyceride levels >200 mg/dl and HDL cholesterol levels <40 mg/dL. A number of clinical trials suggest that treatment with a fibrate may reduce cardiovascular events. However, the results of these trials are inconsistent, probably because many of their participants did not have dyslipidemia. The choice of medications used to treat diabetes can have major implications regarding management of dyslipidemia; metformin, GLP-1 agonists, and pioglitazone all have favorable lipid effects. These agents, as well as the new SGLT2 inhibitors, may reduce cardiovascular events. Summary: Management of dyslipidemia in people with type 2 diabetes should start with statin therapy and optimal glycemic control with agents that have favorable lipid and cardiovascular effects. We believe that there is a role for adding fenofibrate to moderate-intensity statins in selected patients with true dyslipidemia. We propose an algorithm for selecting add-on medications for diabetes (after metformin) based on lipid status.",
keywords = "Cardiovascular disease, Fibrates, Type 2 diabetes",
author = "Abeer Anabtawi and Moriarty, {Patrick M.} and Miles, {John M.}",
year = "2017",
month = "7",
day = "1",
doi = "10.1007/s11886-017-0872-8",
language = "English (US)",
volume = "19",
journal = "Current Cardiology Reports",
issn = "1523-3782",
publisher = "Current Medicine Group",
number = "7",

}

TY - JOUR

T1 - Pharmacologic Treatment of Dyslipidemia in Diabetes

T2 - A Case for Therapies in Addition to Statins

AU - Anabtawi, Abeer

AU - Moriarty, Patrick M.

AU - Miles, John M.

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Purpose of Review: The purpose of the study is to review the use of statins and the role of both non-statin lipid-lowering agents and diabetes-specific medications in the treatment of diabetic dyslipidemia. Recent Findings: Statins have a primary role in the treatment of dyslipidemia in people with type 2 diabetes, defined as triglyceride levels >200 mg/dl and HDL cholesterol levels <40 mg/dL. A number of clinical trials suggest that treatment with a fibrate may reduce cardiovascular events. However, the results of these trials are inconsistent, probably because many of their participants did not have dyslipidemia. The choice of medications used to treat diabetes can have major implications regarding management of dyslipidemia; metformin, GLP-1 agonists, and pioglitazone all have favorable lipid effects. These agents, as well as the new SGLT2 inhibitors, may reduce cardiovascular events. Summary: Management of dyslipidemia in people with type 2 diabetes should start with statin therapy and optimal glycemic control with agents that have favorable lipid and cardiovascular effects. We believe that there is a role for adding fenofibrate to moderate-intensity statins in selected patients with true dyslipidemia. We propose an algorithm for selecting add-on medications for diabetes (after metformin) based on lipid status.

AB - Purpose of Review: The purpose of the study is to review the use of statins and the role of both non-statin lipid-lowering agents and diabetes-specific medications in the treatment of diabetic dyslipidemia. Recent Findings: Statins have a primary role in the treatment of dyslipidemia in people with type 2 diabetes, defined as triglyceride levels >200 mg/dl and HDL cholesterol levels <40 mg/dL. A number of clinical trials suggest that treatment with a fibrate may reduce cardiovascular events. However, the results of these trials are inconsistent, probably because many of their participants did not have dyslipidemia. The choice of medications used to treat diabetes can have major implications regarding management of dyslipidemia; metformin, GLP-1 agonists, and pioglitazone all have favorable lipid effects. These agents, as well as the new SGLT2 inhibitors, may reduce cardiovascular events. Summary: Management of dyslipidemia in people with type 2 diabetes should start with statin therapy and optimal glycemic control with agents that have favorable lipid and cardiovascular effects. We believe that there is a role for adding fenofibrate to moderate-intensity statins in selected patients with true dyslipidemia. We propose an algorithm for selecting add-on medications for diabetes (after metformin) based on lipid status.

KW - Cardiovascular disease

KW - Fibrates

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=85019833829&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019833829&partnerID=8YFLogxK

U2 - 10.1007/s11886-017-0872-8

DO - 10.1007/s11886-017-0872-8

M3 - Review article

C2 - 28528456

AN - SCOPUS:85019833829

VL - 19

JO - Current Cardiology Reports

JF - Current Cardiology Reports

SN - 1523-3782

IS - 7

M1 - 62

ER -